Monday, February 06, 2006
Merger talk to overshadow Boston Scientific results
Wall Street is craving more details on Boston Scientific's road map for integrating its $27 billion acquisition of Guidant, which the company wrested away from Johnson & Johnson last month after a high-stakes bidding war.(ABC)(Reuters)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment